Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leigh MacConell

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Current Medical Research and Opinion|March 14, 2014
Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titrationJohn B Buse, Jenny Han, Stephan Miller, et al.
Current Medical Research and Opinion|September 13, 2008
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over studyRalph A DeFronzo, Ted Okerson, Prabhakar Viswanathan, et al.
Diabetes Care|March 14, 2007
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetesDennis Kim, Leigh MacConell, Dongliang Zhuang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 8, 2020
Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitisAlbert Parés, Mitchell Shiffman, Victor Vargas, et al.
Diabetes Care|February 24, 2012
Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeksMichaela Diamant, Luc Van Gaal, Stephen Stranks, et al.
Cardiovascular Diabetology|January 30, 2010
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot studyAnne Gill, Byron J Hoogwerf, Jude Burger, et al.
Lancet (London, England)|June 29, 2010
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trialRichard M Bergenstal, Carol Wysham, Leigh Macconell, et al.
British Journal of Clinical Pharmacology|August 14, 2012
Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjectsBörje Darpö, Philip Sager, Leigh MacConell, et al.
Hepatology Communications|June 9, 2018
Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitisMarco Carbone, Maren H Harms, Willem J Lammers, et al.
JHEP Reports : Innovation in Hepatology|December 15, 2020
Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitisMaren H Harms, Gideon M Hirschfield, Annarosa Floreani, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Current Medical Research and Opinion|March 14, 2014
Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titrationJohn B Buse, Jenny Han, Stephan Miller, et al.
Current Medical Research and Opinion|September 13, 2008
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over studyRalph A DeFronzo, Ted Okerson, Prabhakar Viswanathan, et al.
Diabetes Care|March 14, 2007
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetesDennis Kim, Leigh MacConell, Dongliang Zhuang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 8, 2020
Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitisAlbert Parés, Mitchell Shiffman, Victor Vargas, et al.
Diabetes Care|February 24, 2012
Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeksMichaela Diamant, Luc Van Gaal, Stephen Stranks, et al.
Cardiovascular Diabetology|January 30, 2010
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot studyAnne Gill, Byron J Hoogwerf, Jude Burger, et al.
Lancet (London, England)|June 29, 2010
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trialRichard M Bergenstal, Carol Wysham, Leigh Macconell, et al.
British Journal of Clinical Pharmacology|August 14, 2012
Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjectsBörje Darpö, Philip Sager, Leigh MacConell, et al.
Hepatology Communications|June 9, 2018
Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitisMarco Carbone, Maren H Harms, Willem J Lammers, et al.
JHEP Reports : Innovation in Hepatology|December 15, 2020
Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitisMaren H Harms, Gideon M Hirschfield, Annarosa Floreani, et al.
Pageof 4